Effects of estrogen agonists on amphetamine-stimulated striatal dopamine release
Article first published online: 7 DEC 1998
Copyright © 1998 Wiley-Liss, Inc.
Volume 29, Issue 4, pages 379–391, August 1998
How to Cite
Xiao, L. and Becker, J. B. (1998), Effects of estrogen agonists on amphetamine-stimulated striatal dopamine release. Synapse, 29: 379–391. doi: 10.1002/(SICI)1098-2396(199808)29:4<379::AID-SYN10>3.0.CO;2-M
- Issue published online: 7 DEC 1998
- Article first published online: 7 DEC 1998
- Manuscript Accepted: 30 JAN 1998
- Manuscript Received: 11 SEP 1997
- NSF. Grant Numbers: BNS9021900, NICHD5T32-HD07048
- estrogen agonists;
- hormone replacement therapy;
Based upon the observation that estrogen acts in the striatum to rapidly modulate dopamine (DA) neural transmission and DA-mediated behaviors, it has been postulated that these effects of estrogen are mediated by a specific, membrane-bound receptor mechanism. To further characterize the pharmacological specificity of the estrogen binding site, the present experiments examine effects of various estrogen agonists on amphetamine (AMPH)-induced DA release from striatal tissue of ovariectomized female rats, using a superfusion method. Catechol estrogens 4-, and 2-hydroxyestradiol, but not 2-methoxyestradiol, significantly enhance AMPH-induced striatal DA release. Estrogen metabolites, estrone and estriol, and the non-steroidal estrogen analog, diethylstilbestrol, are without effects. Estradiol conjugated to bovine serum albumin (BSA) mimics the effect of estradiol to enhance stimulated striatal DA release. These results indicate that the steroidal configuration and hydroxylation on the A-ring of estrogenic compounds may be important determinants of ligand binding to the putative estrogen binding site in the striatum. Furthermore, the effectiveness of the estradiol conjugated to BSA reinforces the idea of an external membrane-bound receptor binding site in the striatum. Synapse 29:379–391, 1998. © 1998 Wiley-Liss, Inc.